Marc Herz

Marc Herz, PhD is a founder of Multimeric who has extensive experience in vaccine development. He was previously CEO of Pharmexa, Inc. (formerly Epimmune, Inc.), a publicly traded subsidiary of Pharmexa A/S that developed vaccines and cancer immunotherapies. At Pharmexa, he was responsible for 28 scientists and administrators and directed company strategy, business development, investor relations, and participated in multiple rounds of public fundraising. Marc received a Bachelor’s degree from Bowdoin College and a Ph.D. in Immunology from the University of Colorado Health Sciences Center and the National Jewish Medical and Research Center. He is currently a co-founder of GRI Bio, Inc., which is a biotech company focused on inflammatory, fibrotic and autoimmune diseases.